BOULDER, Colo.–(BUSINESS WIRE)–VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. The overall objective of the research proposal titled “Optimization and Production of Single-Shot Vaccines for Melioidosis and Glanders” is to apply VitriVax’s single-shot and thermostabilization technology (ALTA™) to the lead B. pseudomallei (Bp) vaccine candidate, which is cu
Click here to view original post
News
Rob Renzi Joins Catalyst Solutions as Chief Growth Officer
Experienced Health Care Leader to Drive Growth GREENWOOD VILLAGE, Colo., Oct. 8, 2024 /PRNewswire/ — Catalyst Solutions, a leader in innovative solutions to Health Plans, has announced today that Rob Renzi has joined the company […]
News
Céline Dion’s Doctor Keeps Her Eye on the Prize: Advancing Medicine
While this year has taken Amanda Piquet, MD, to rarefied heights – becoming the inaugural Céline Dion Foundation Endowed Chair in Autoimmune Neurology and getting singled out by Dion at the premiere of the singer’s […]
News
RheumaGen Announces Funding Agreement with Beyond Celiac Investments to Accelerate Treatments Towards a Cure in Celiac Disease
Investment to progress RheumaGen’s celiac disease program through early development as a potential transformational gene therapy AURORA, Colo., Dec. 22, 2025 /PRNewswire/ — RheumaGen, Inc., a cell and gene therapy company engineering a new class […]
